Abstract
Pancreatic cancer (PC) ranks among the most lethal malignancies worldwide with a dismal survival rate. Several years of basic and clinical research using a plethora of mouse models have led to significant advancements in developing therapeutic strategies against PC; however, the overall survival of PC patients has not seen much improvement. The insufficiency in replicating the favorable preclinical outcome for most cancer drugs in PC patients stems from multiple factors including interspecies genomic variability, intra- and inter-patient tumor heterogeneity, and ineffective study design in terms of drug dosing and end-point selection. The current chapter encompasses the various mouse models of PC used in drug discovery research, their current application, strengths, and weaknesses. Further, we have explored the future goals and realistic challenges that need to be addressed in order to develop potentially predictive mouse models for better clinical translation of novel cancer therapeutics.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
